NVS

Novartis AG Form 6-K Summary: Second Quarter 2010

Business Context and Reporting Period

This Form 6-K reports the unaudited financial results for Novartis AG for the second quarter and first half ended June 30, 2010. The Swiss-based pharmaceutical company reported strong double-digit growth driven by portfolio rejuvenation, innovation, and productivity initiatives. The period included significant regulatory milestones, including FDA approvals for Tasigna and Zortress, and a unanimous FDA Advisory Committee recommendation for FTY720.

Key Financial Metrics

Balance Sheet & Liquidity: Total assets stood at USD 96.9 billion. Financial debt totaled USD 18.6 billion (USD 5.4 billion current, USD 13.2 billion non-current). Net liquidity increased to USD 4.4 billion from USD 3.5 billion at year-end 2009. The debt-to-equity ratio rose to 0.33:1.

Material Changes vs. Prior Period

• Revenue Growth: Net sales grew 11% (12% in constant currencies) in Q2, driven by a 12 percentage point volume increase. Recently launched products contributed 21% of total sales (USD 2.4 billion).
• Margin Expansion: Operating income margin improved 2.9 percentage points to 25.3%. Core operating margin rose 2.7 percentage points to 28.0%.
• Divisional Performance:
  • Pharmaceuticals: Sales up 8% (cc); Oncology and Neuroscience/Ophthalmics were key growth drivers.
  • Vaccines & Diagnostics: Sales surged 135% (cc) to USD 0.6 billion, largely due to USD 0.2 billion in A(H1N1) pandemic vaccine sales.
  • Sandoz: Sales up 13% (cc) to USD 2.0 billion, driven by biosimilars (up 66%) and the EBEWE Pharma acquisition.
  • Consumer Health: Sales up 7% (cc) to USD 1.5 billion.
• Exceptional Items: Operating income included a USD 265 million pension curtailment gain, offset by USD 231 million in litigation/legal provisions and USD 82 million in asset impairments.

Guidance, Outlook, and Risks

Outlook: Novartis raised its full-year sales guidance to mid- to high-single-digit growth in constant currencies (excluding Alcon). Management expects operating and core operating margins to increase in 2010. The impact of exchange rates is expected to be broadly neutral on operating income for the full year, though slightly negative on sales.

Strategic Priorities: Focus remains on innovation (58 new molecular entities in development), growth (expanding in emerging markets), and productivity (cost reduction and efficiency).

Key Risks and Contingencies:

• Alcon Acquisition: Closing of the 77% stake acquisition is expected in late Q3 or Q4 2010, pending regulatory approvals. Financing includes a USD 5 billion bond issuance in March 2010.
• Legal Proceedings: Significant provisions exist for US government investigations (Trileptal, Five Products) totaling USD 422.5 million. Ongoing litigation includes Zometa/Aredia product liability, Zelnorm settlements, and gender discrimination cases (settled for up to USD 152.5 million).
• Regulatory: Pending decisions on FTY720 (MS), Afinitor (various indications), and MenB vaccine.

Investor Verification Checklist

• Verify the sustainability of A(H1N1) vaccine revenue contributions in future quarters, as the campaign is largely complete.
• Monitor the timeline and regulatory approval status for the Alcon acquisition and the associated financing costs.
• Review the status of ongoing US government investigations and potential additional legal settlements beyond current provisions.
• Assess the impact of currency fluctuations on future reported results, given the expectation of a negative impact on sales in the second half.
• Track the commercial uptake of recently launched products (e.g., Tasigna, Exforge, Lucentis) to ensure they offset patent expirations.